Gregory P. Botta, MD, PhD

Gregory Botta, MD, PhD, discusses the diagnosis and treatment of patients with esophageal squamous cell carcinoma.

Gregory Botta, MD, PhD, discusses unmet needs in the salvage setting of gastrointestinal cancers.

Gregory Botta, MD, PhD, discusses the rationale for investigating CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Gregory Botta, MD, PhD, discusses the evaluation of CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Gregory P. Botta, MD, PhD, highlights key trials of interest exploring ctDNA analyses to better inform treatment decisions for patients with rectal cancers.

What to know about the design and results of the CIRCULATE-Japan study in colorectal cancer, in terms of using ctDNA analyses to help inform treatment decisions in the postoperative setting.

Current trials investigating the potential of ctDNA analyses in pancreatic cancer.

Dr Gregory P. Botta reacts to results of a study that recently explored the association of tumor-informed and personalized ctDNA with patient survival outcomes in pancreatic cancer, as presented at ASCO GI 2022.

The potential clinical applications of ctDNA analyses in pancreatic cancer.

The present role of minimal residual disease in solid tumor cancers, and current evaluations further exploring its potential in pancreatic and colorectal cancer.